<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01969851</url>
  </required_header>
  <id_info>
    <org_study_id>SP0966</org_study_id>
    <secondary_id>2012-001446-18</secondary_id>
    <nct_id>NCT01969851</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Safety and Efficacy of Lacosamide Added to the Patients Current Therapy in Patients Aged 1 Month to Less Than 18 Years Old With Epilepsy Syndromes Associated With Generalized Seizures.</brief_title>
  <official_title>A MULTI-CENTER, OPEN-LABEL, EXPLORATORY STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF LACOSAMIDE AS ADJUNCTIVE THERAPY IN SUBJECTS ≥1 MONTH TO &lt;18 YEARS WITH EPILEPSY SYNDROMES ASSOCIATED WITH GENERALIZED SEIZURES.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      SP0966 is an exploratory study to investigate safety and efficacy of Lacosamide (LCM) in
      children with epilepsy syndromes associated with generalized seizures. LCM will be added to
      current antiepileptic treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SP0966 is a Phase 2, multicenter, open-label exploratory study designed to assess the safety
      and preliminary efficacy of oral lacosamide as adjunctive therapy for epilepsy syndromes
      associated with generalized seizures in pediatric subjects ≥1 month to &lt;18 years of age.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 13, 2014</start_date>
  <completion_date type="Actual">April 10, 2018</completion_date>
  <primary_completion_date type="Actual">April 10, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Changes in Count of Generalized Spike-wave Discharges on 24-hour Ambulatory Electroencephalogram (EEG) From Visit 2 to Visit 6</measure>
    <time_frame>From Baseline (Day 1) to Visit 6 (Week 6)</time_frame>
    <description>The mean change in the count of generalized spike-wave discharges was presented. Visit 6 (Week 6) was the End of the Titration Period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change in Days With Any Generalized Seizures (Absence, Myoclonic, Clonic, Tonic, Tonic-clonic, Atonic, Partial Evolving to Secondarily Generalized) Per 28 Days From the Baseline Period to the Maintenance Period (Approximately 24 Weeks)</measure>
    <time_frame>Baseline Period to the Maintenance Period (approximately 24 weeks)</time_frame>
    <description>The mean change in the count of days with generalized seizures was presented.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Changes in Count of 3 Hz Spike-wave Discharges (During Waking Hours) on 24-hour Ambulatory EEG From Visit 2 to Visit 6</measure>
    <time_frame>From Baseline (Day 1) to Visit 6 (Week 6)</time_frame>
    <description>The mean change in the count of 3 Hertz (Hz) spike-wave discharges was presented. Visit 6 (Week 6) was the End of the Titration Period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subject Withdrawals Due to Adverse Events From Baseline to End of Study (Approximately 32 Weeks)</measure>
    <time_frame>From Baseline to End of Study (approximately 32 weeks)</time_frame>
    <description>An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Experiencing at Least 1 Treatment-emergent Adverse Event From Baseline to End of Study (Approximately 32 Weeks)</measure>
    <time_frame>From Baseline to End of Study (approximately 32 weeks)</time_frame>
    <description>An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Lacosamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lacosamide</intervention_name>
    <description>Oral intake twice daily of tablet (100 mg or 50 mg) or syrup formulation (10 mg/ml).
Total daily dose will be titrated over a period of 6 weeks with starting dose of 100 mg/day or 2 mg/kg/day up to doses not exceeding 600 mg/day or 12 mg/kg/day tablet or syrup, respectively. Followed by a 12 week maintenance period with stable dosing of at least 200 mg/day or 4 mg/kg/day tablet or syrup, respectively.</description>
    <arm_group_label>Lacosamide</arm_group_label>
    <other_name>Vimpat</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A signed informed consent has been obtained from the parent/legal representative and
             assent has been obtained from the subject (when possible)

          -  Subject and caregiver are willing and able to comply with all study requirements
             including maintaining a daily seizure diary

          -  Subject is male or female, ≥1 month to &lt;18 years of age

          -  Subject has a diagnosis of uncontrolled epilepsy with generalized seizures (Type II)
             according to the International Classification of Epileptic Seizures (1981). The
             underlying epilepsy syndrome should be documented. Diagnosis should have been
             established by clinical history and an Electroencephalogram (EEG) with generalized
             spike-wave discharges. Documentation of the EEG finding of generalized spike waves
             (EEG recording or a report) is required. The EEG should have been performed no more
             than 18 months prior to Visit 1 (with no change to diagnosis or seizure types during
             this time)

          -  Subject must have experienced 2 or more events (typical generalized seizures
             associated with diagnosed epilepsy syndrome) within the 6-week prospective Baseline
             Period

          -  Subject is on a stable dosage regimen of 1 to 3 antiepileptic drugs (AEDs). The daily
             dosage regimen of concomitant AED therapy must be kept constant for a period of at
             least 4 weeks prior to the Baseline Period

          -  Vagal nerve stimulation is allowed and will not be counted as a concomitant AED. The
             vagus nerve stimulation (VNS) device must be implanted for at least 6 months before
             Visit 1, and the device settings must be stable for at least 4 weeks before Visit 1
             and be kept stable during the Baseline Period and the Treatment Period. Use of the VNS
             device magnet is allowed

          -  Body weight at Visit 1 is at least 4 kg for infants.

          -  Females of childbearing potential must have a negative pregnancy test at Visit 1

          -  Subjects with West Syndrome are eligible if Baseline EEG demonstrates hypsarrhythmia
             despite treatment with at least 2 AEDs appropriate for the treatment of this syndrome

        Exclusion Criteria:

          -  Subject has previously participated in this study, subject has been assigned to
             Lacosamide (LCM) in a previous LCM study, or subject has ever received LCM

          -  Subject is currently participating or has participated within the last 2 months in any
             study of an investigational drug or experimental device

          -  Subject has a history of convulsive status epilepticus within 1 month prior to Visit 1

          -  Subject has a current or previous diagnosis of pseudoseizures, conversion disorders,
             or other nonepileptic ictal events that could be confused with seizures

          -  Subject has exclusively typical absence (Type IIA1) or atypical absence (Type IIA2)
             seizures (no other generalized seizure types are reported), or has only partial-onset
             seizures (Type I)

          -  Subject has any medical or psychiatric condition that, in the opinion of the
             investigator, could jeopardize the subject's health or would compromise the subject's
             ability to participate in this study

          -  Subject ≥6 years of age has a lifetime history of suicide attempt (including an actual
             attempt, interrupted attempt, or aborted attempt), or has suicidal ideation in the
             past 6 months as indicated by a positive response (&quot;Yes&quot;) to either Question 4 or
             Question 5 of the Columbia Suicide Severity Rating Scale (C-SSRS) at Screening

          -  Subject has a known hypersensitivity to any components of the investigational
             medicinal product (IMP)

          -  Subject has a medical condition that could reasonably be expected to interfere with
             drug absorption, distribution, metabolism, or excretion

          -  Subject has a known history of severe anaphylactic reaction or serious blood
             dyscrasias

          -  Subject has any history of alcohol or drug abuse within the previous 2 years

          -  Subject has an acute or sub-acutely progressive central nervous system disease.
             Subject has epilepsy secondary to a progressing cerebral disease or any other
             progressively neurodegenerative disease (malignant brain tumor or Rasmussen Syndrome)

          -  Subject has alanine aminotransferase (ALT), aspartate aminotransferase (AST), or total
             bilirubin levels ≥2x the upper limit of normal (ULN) or has alkaline phosphatase
             levels ≥3x ULN

          -  Subject has impaired renal function (ie, creatinine clearance is lower than 30 mL/min)
             at Visit 1

          -  Subject has sick sinus syndrome without a pacemaker, or second or third degree
             atrioventricular (AV) block

          -  Subjects with second- or third-degree heart block are excluded from SP0966
             (NCT01969851), without the requirement of being at rest

          -  Subject has hemodynamically significant heart disease (eg, heart failure)

          -  Subject has an arrhythmic heart condition requiring medical therapy

          -  Subject has a known cardiac sodium channelopathy, such as Brugada syndrome

          -  Female subject who is pregnant or nursing, and/or a female subject of childbearing
             potential who is not surgically sterile or does not practice 1 highly effective method
             of contraception (according to International Conference on Harmonisation [ICH]
             guidance. Female subject of childbearing potential taking enzyme inducing
             antiepileptic drugs(EI AEDs) (carbamazepine, phenytoin, barbiturates, primidone,
             topiramate, oxcarbazepine) who is not surgically sterile or does not practice 1 highly
             effective method of contraception according to the World Health Organization
             recommendation (ie, depot medroxyprogesterone acetate, norethisterone enantate,
             intrauterine devices, combined injectables, and progestogen implants) with
             administration of enzyme inducing antiepileptic drugs (EI-AEDs) or does not practice 2
             combined methods of contraception (ie, combined hormonal contraception plus barrier
             method with spermicidal agent), unless sexually abstinent, for the duration of the
             study

          -  Subject has been treated with vigabatrin and experienced any vision loss. Subjects who
             have received vigabatrin in the past must have documentation of an assessment for
             vision loss prior to study entry or documentation of why visual field testing cannot
             be performed

          -  Subject has been treated with felbamate and has experienced any serious toxicity
             issues (defined as liver failure, aplastic anemia) with this treatment. Subjects
             treated with felbamate for less than 12 months are excluded. Note: any subject who has
             been treated with felbamate for at least 12 months and has not experienced serious
             toxicity issues is eligible

          -  Subject is taking monoamine oxidase (MAO) inhibitors or narcotic analgesics.

          -  Subject is on a ketogenic or other specialized diet. If he/she was on a specialized
             diet in the past, he/she must be off the diet for at least 2 months prior to the
             Screening Visit (Visit 1)

          -  Subject has primary generalized tonic-clonic seizures with a diagnosis of idiopathic
             generalized epilepsy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Cares</last_name>
    <role>Study Director</role>
    <affiliation>+1 844 599 2273</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>103</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>101</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>104</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>112</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>108</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>107</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>309</name>
      <address>
        <city>Ile-De-France</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>303</name>
      <address>
        <city>Lyon Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>701</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>702</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>703</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>704</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>705</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>154</name>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>807</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>801</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>805</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>802</name>
      <address>
        <city>Szczecin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Hungary</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Croatia</country>
    <country>Germany</country>
    <country>Romania</country>
  </removed_countries>
  <link>
    <url>https://www.vimpathcp.com/vimpat-prescribing-information.pdf?v=1491846793</url>
    <description>Product Information</description>
  </link>
  <link>
    <url>http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>October 21, 2013</study_first_submitted>
  <study_first_submitted_qc>October 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2013</study_first_posted>
  <results_first_submitted>April 10, 2019</results_first_submitted>
  <results_first_submitted_qc>May 2, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 7, 2019</results_first_posted>
  <last_update_submitted>May 2, 2019</last_update_submitted>
  <last_update_submitted_qc>May 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lacosamide</keyword>
  <keyword>Vimpat</keyword>
  <keyword>Epilepsy</keyword>
  <keyword>Children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Seizures</mesh_term>
    <mesh_term>Epileptic Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lacosamide</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 6, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/51/NCT01969851/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 26, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/51/NCT01969851/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study started to enroll patients in February 2014 and concluded in April 2018.</recruitment_details>
      <pre_assignment_details>The Participant Flow refers to the Safety Set which consisted of all enrolled subjects who took at least 1 dose of lacosamide (LCM).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Lacosamide 1 Month - &lt;4 Years</title>
          <description>Subjects, aged 1 month to &lt;4 years, who were administered Lacosamide oral solution (for subjects weighing &lt;50 kg) or tablet (for subjects weighing &gt;=50 kg). The initial dose of 2 mg/kg/day (for subjects weighing &lt;50 kg), or 100 mg/day (for subjects weighing &gt;=50 kg) was titrated to optimize tolerability and seizure control to at least 4 mg/kg/day for subjects weighing &lt;50 kg, or 200 mg/day for subjects weighing &gt;=50 kg; not to exceed 12 mg/kg/day for subjects weighing &lt;50 kg, or 600 mg/day in subjects weighing &gt;=50 kg.</description>
        </group>
        <group group_id="P2">
          <title>Lacosamide 4 Years - &lt;12 Years</title>
          <description>Subjects, aged 4 years to &lt;12 years, who were administered Lacosamide oral solution (for subjects weighing &lt;50 kg) or tablet (for subjects weighing &gt;=50 kg). The initial dose of 2 mg/kg/day (for subjects weighing &lt;50 kg), or 100 mg/day (for subjects weighing &gt;=50 kg) was titrated to optimize tolerability and seizure control to at least 4 mg/kg/day for subjects weighing &lt;50kg, or 200 mg/day for subjects weighing &gt;=50 kg; not to exceed 12 mg/kg/day for subjects weighing &lt;50 kg, or 600 mg/day in subjects weighing &gt;=50 kg.</description>
        </group>
        <group group_id="P3">
          <title>Lacosamide 12 Years - &lt;18 Years</title>
          <description>Subjects, aged 12 years to &lt;18 years, who were administered Lacosamide oral solution (for subjects weighing &lt;50 kg) or tablet (for subjects weighing &gt;=50 kg). The initial dose of 2 mg/kg/day (for subjects weighing &lt;50 kg), or 100 mg/day (for subjects weighing &gt;=50 kg) was titrated to optimize tolerability and seizure control to at least 4 mg/kg/day for subjects weighing &lt;50kg, or 200 mg/day for subjects weighing &gt;=50 kg; not to exceed 12 mg/kg/day for subjects weighing &lt;50 kg, or 600 mg/day in subjects weighing &gt;=50 kg.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No effective dose in Titration period</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Baseline Characteristics refer to the Safety Set which consisted of all enrolled subjects who took at least 1 dose of lacosamide (LCM).</population>
      <group_list>
        <group group_id="B1">
          <title>Lacosamide 1 Month - &lt;4 Years</title>
          <description>Subjects, aged 1 month to &lt;4 years, who were administered Lacosamide oral solution (for subjects weighing &lt;50 kg) or tablet (for subjects weighing &gt;=50 kg). The initial dose of 2 mg/kg/day (for subjects weighing &lt;50 kg), or 100 mg/day (for subjects weighing &gt;=50 kg) was titrated to optimize tolerability and seizure control to at least 4 mg/kg/day for subjects weighing &lt;50 kg, or 200 mg/day for subjects weighing &gt;=50 kg; not to exceed 12 mg/kg/day for subjects weighing &lt;50 kg, or 600 mg/day in subjects weighing &gt;=50 kg.</description>
        </group>
        <group group_id="B2">
          <title>Lacosamide 4 Years - &lt;12 Years</title>
          <description>Subjects, aged 4 years to &lt;12 years, who were administered Lacosamide oral solution (for subjects weighing &lt;50 kg) or tablet (for subjects weighing &gt;=50 kg). The initial dose of 2 mg/kg/day (for subjects weighing &lt;50 kg), or 100 mg/day (for subjects weighing &gt;=50 kg) was titrated to optimize tolerability and seizure control to at least 4 mg/kg/day for subjects weighing &lt;50kg, or 200 mg/day for subjects weighing &gt;=50 kg; not to exceed 12 mg/kg/day for subjects weighing &lt;50 kg, or 600 mg/day in subjects weighing &gt;=50 kg.</description>
        </group>
        <group group_id="B3">
          <title>Lacosamide 12 Years - &lt;18 Years</title>
          <description>Subjects, aged 12 years to &lt;18 years, who were administered Lacosamide oral solution (for subjects weighing &lt;50 kg) or tablet (for subjects weighing &gt;=50 kg). The initial dose of 2 mg/kg/day (for subjects weighing &lt;50 kg), or 100 mg/day (for subjects weighing &gt;=50 kg) was titrated to optimize tolerability and seizure control to at least 4 mg/kg/day for subjects weighing &lt;50kg, or 200 mg/day for subjects weighing &gt;=50 kg; not to exceed 12 mg/kg/day for subjects weighing &lt;50 kg, or 600 mg/day in subjects weighing &gt;=50 kg.</description>
        </group>
        <group group_id="B4">
          <title>Total Title</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="21"/>
            <count group_id="B4" value="55"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.716" spread="0.765"/>
                    <measurement group_id="B2" value="6.969" spread="1.998"/>
                    <measurement group_id="B3" value="14.753" spread="1.766"/>
                    <measurement group_id="B4" value="9.168" spread="4.994"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Changes in Count of Generalized Spike-wave Discharges on 24-hour Ambulatory Electroencephalogram (EEG) From Visit 2 to Visit 6</title>
        <description>The mean change in the count of generalized spike-wave discharges was presented. Visit 6 (Week 6) was the End of the Titration Period.</description>
        <time_frame>From Baseline (Day 1) to Visit 6 (Week 6)</time_frame>
        <population>The Safety Set (SS) included all enrolled subjects who took at least 1 dose of lacosamide (LCM).</population>
        <group_list>
          <group group_id="O1">
            <title>Lacosamide 1 Month - &lt;4 Years SS</title>
            <description>Subjects, aged 1 month to &lt;4 years, who were administered Lacosamide oral solution (for subjects weighing &lt;50 kg) or tablet (for subjects weighing &gt;=50 kg). The initial dose of 2 mg/kg/day (for subjects weighing &lt;50 kg), or 100 mg/day (for subjects weighing &gt;=50 kg) was titrated to optimize tolerability and seizure control to at least 4 mg/kg/day for subjects weighing &lt;50 kg, or 200 mg/day for subjects weighing &gt;=50 kg; not to exceed 12 mg/kg/day for subjects weighing &lt;50 kg, or 600 mg/day in subjects weighing &gt;=50 kg.</description>
          </group>
          <group group_id="O2">
            <title>Lacosamide 4 Years - &lt;2 Years SS</title>
            <description>Subjects, aged 4 years to &lt;12 years, who were administered Lacosamide oral solution (for subjects weighing &lt;50 kg) or tablet (for subjects weighing &gt;=50 kg). The initial dose of 2 mg/kg/day (for subjects weighing &lt;50 kg), or 100 mg/day (for subjects weighing &gt;=50 kg) was titrated to optimize tolerability and seizure control to at least 4 mg/kg/day for subjects weighing &lt;50kg, or 200 mg/day for subjects weighing &gt;=50 kg; not to exceed 12 mg/kg/day for subjects weighing &lt;50 kg, or 600 mg/day in subjects weighing &gt;=50 kg.</description>
          </group>
          <group group_id="O3">
            <title>Lacosamide 12 Years - &lt;18 Years SS</title>
            <description>Subjects, aged 12 years to &lt;18 years, who were administered Lacosamide oral solution (for subjects weighing &lt;50 kg) or tablet (for subjects weighing &gt;=50 kg). The initial dose of 2 mg/kg/day (for subjects weighing &lt;50 kg), or 100 mg/day (for subjects weighing &gt;=50 kg) was titrated to optimize tolerability and seizure control to at least 4 mg/kg/day for subjects weighing &lt;50kg, or 200 mg/day for subjects weighing &gt;=50 kg; not to exceed 12 mg/kg/day for subjects weighing &lt;50 kg, or 600 mg/day in subjects weighing &gt;=50 kg.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Changes in Count of Generalized Spike-wave Discharges on 24-hour Ambulatory Electroencephalogram (EEG) From Visit 2 to Visit 6</title>
          <description>The mean change in the count of generalized spike-wave discharges was presented. Visit 6 (Week 6) was the End of the Titration Period.</description>
          <population>The Safety Set (SS) included all enrolled subjects who took at least 1 dose of lacosamide (LCM).</population>
          <units>discharges</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.55" spread="257.32"/>
                    <measurement group_id="O2" value="-166.22" spread="447.80"/>
                    <measurement group_id="O3" value="-203.12" spread="432.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in Days With Any Generalized Seizures (Absence, Myoclonic, Clonic, Tonic, Tonic-clonic, Atonic, Partial Evolving to Secondarily Generalized) Per 28 Days From the Baseline Period to the Maintenance Period (Approximately 24 Weeks)</title>
        <description>The mean change in the count of days with generalized seizures was presented.</description>
        <time_frame>Baseline Period to the Maintenance Period (approximately 24 weeks)</time_frame>
        <population>The Safety Set (SS) included all enrolled subjects who took at least 1 dose of lacosamide (LCM).</population>
        <group_list>
          <group group_id="O1">
            <title>Lacosamide 1 Month - &lt;4 Years SS</title>
            <description>Subjects, aged 1 month to &lt;4 years, who were administered Lacosamide oral solution (for subjects weighing &lt;50 kg) or tablet (for subjects weighing &gt;=50 kg). The initial dose of 2 mg/kg/day (for subjects weighing &lt;50 kg), or 100 mg/day (for subjects weighing &gt;=50 kg) was titrated to optimize tolerability and seizure control to at least 4 mg/kg/day for subjects weighing &lt;50 kg, or 200 mg/day for subjects weighing &gt;=50 kg; not to exceed 12 mg/kg/day for subjects weighing &lt;50 kg, or 600 mg/day in subjects weighing &gt;=50 kg.</description>
          </group>
          <group group_id="O2">
            <title>Lacosamide 4 Years - &lt;2 Years SS</title>
            <description>Subjects, aged 4 years to &lt;12 years, who were administered Lacosamide oral solution (for subjects weighing &lt;50 kg) or tablet (for subjects weighing &gt;=50 kg). The initial dose of 2 mg/kg/day (for subjects weighing &lt;50 kg), or 100 mg/day (for subjects weighing &gt;=50 kg) was titrated to optimize tolerability and seizure control to at least 4 mg/kg/day for subjects weighing &lt;50kg, or 200 mg/day for subjects weighing &gt;=50 kg; not to exceed 12 mg/kg/day for subjects weighing &lt;50 kg, or 600 mg/day in subjects weighing &gt;=50 kg.</description>
          </group>
          <group group_id="O3">
            <title>Lacosamide 12 Years - &lt;18 Years SS</title>
            <description>Subjects, aged 12 years to &lt;18 years, who were administered Lacosamide oral solution (for subjects weighing &lt;50 kg) or tablet (for subjects weighing &gt;=50 kg). The initial dose of 2 mg/kg/day (for subjects weighing &lt;50 kg), or 100 mg/day (for subjects weighing &gt;=50 kg) was titrated to optimize tolerability and seizure control to at least 4 mg/kg/day for subjects weighing &lt;50kg, or 200 mg/day for subjects weighing &gt;=50 kg; not to exceed 12 mg/kg/day for subjects weighing &lt;50 kg, or 600 mg/day in subjects weighing &gt;=50 kg.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Days With Any Generalized Seizures (Absence, Myoclonic, Clonic, Tonic, Tonic-clonic, Atonic, Partial Evolving to Secondarily Generalized) Per 28 Days From the Baseline Period to the Maintenance Period (Approximately 24 Weeks)</title>
          <description>The mean change in the count of days with generalized seizures was presented.</description>
          <population>The Safety Set (SS) included all enrolled subjects who took at least 1 dose of lacosamide (LCM).</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" spread="6.63"/>
                    <measurement group_id="O2" value="-1.90" spread="3.76"/>
                    <measurement group_id="O3" value="-3.38" spread="6.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Changes in Count of 3 Hz Spike-wave Discharges (During Waking Hours) on 24-hour Ambulatory EEG From Visit 2 to Visit 6</title>
        <description>The mean change in the count of 3 Hertz (Hz) spike-wave discharges was presented. Visit 6 (Week 6) was the End of the Titration Period.</description>
        <time_frame>From Baseline (Day 1) to Visit 6 (Week 6)</time_frame>
        <population>The Safety Set (SS) included all enrolled subjects who took at least 1 dose of lacosamide (LCM).</population>
        <group_list>
          <group group_id="O1">
            <title>Lacosamide 1 Month - &lt;4 Years SS</title>
            <description>Subjects, aged 1 month to &lt;4 years, who were administered Lacosamide oral solution (for subjects weighing &lt;50 kg) or tablet (for subjects weighing &gt;=50 kg). The initial dose of 2 mg/kg/day (for subjects weighing &lt;50 kg), or 100 mg/day (for subjects weighing &gt;=50 kg) was titrated to optimize tolerability and seizure control to at least 4 mg/kg/day for subjects weighing &lt;50 kg, or 200 mg/day for subjects weighing &gt;=50 kg; not to exceed 12 mg/kg/day for subjects weighing &lt;50 kg, or 600 mg/day in subjects weighing &gt;=50 kg.</description>
          </group>
          <group group_id="O2">
            <title>Lacosamide 4 Years - &lt;2 Years SS</title>
            <description>Subjects, aged 4 years to &lt;12 years, who were administered Lacosamide oral solution (for subjects weighing &lt;50 kg) or tablet (for subjects weighing &gt;=50 kg). The initial dose of 2 mg/kg/day (for subjects weighing &lt;50 kg), or 100 mg/day (for subjects weighing &gt;=50 kg) was titrated to optimize tolerability and seizure control to at least 4 mg/kg/day for subjects weighing &lt;50kg, or 200 mg/day for subjects weighing &gt;=50 kg; not to exceed 12 mg/kg/day for subjects weighing &lt;50 kg, or 600 mg/day in subjects weighing &gt;=50 kg.</description>
          </group>
          <group group_id="O3">
            <title>Lacosamide 12 Years - &lt;18 Years SS</title>
            <description>Subjects, aged 12 years to &lt;18 years, who were administered Lacosamide oral solution (for subjects weighing &lt;50 kg) or tablet (for subjects weighing &gt;=50 kg). The initial dose of 2 mg/kg/day (for subjects weighing &lt;50 kg), or 100 mg/day (for subjects weighing &gt;=50 kg) was titrated to optimize tolerability and seizure control to at least 4 mg/kg/day for subjects weighing &lt;50kg, or 200 mg/day for subjects weighing &gt;=50 kg; not to exceed 12 mg/kg/day for subjects weighing &lt;50 kg, or 600 mg/day in subjects weighing &gt;=50 kg.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Changes in Count of 3 Hz Spike-wave Discharges (During Waking Hours) on 24-hour Ambulatory EEG From Visit 2 to Visit 6</title>
          <description>The mean change in the count of 3 Hertz (Hz) spike-wave discharges was presented. Visit 6 (Week 6) was the End of the Titration Period.</description>
          <population>The Safety Set (SS) included all enrolled subjects who took at least 1 dose of lacosamide (LCM).</population>
          <units>count of discharges</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.14" spread="0.42"/>
                    <measurement group_id="O2" value="-1.60" spread="9.92"/>
                    <measurement group_id="O3" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subject Withdrawals Due to Adverse Events From Baseline to End of Study (Approximately 32 Weeks)</title>
        <description>An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment.</description>
        <time_frame>From Baseline to End of Study (approximately 32 weeks)</time_frame>
        <population>The Safety Set (SS) included all enrolled subjects who took at least 1 dose of lacosamide (LCM).</population>
        <group_list>
          <group group_id="O1">
            <title>Lacosamide 1 Month - &lt;4 Years SS</title>
            <description>Subjects, aged 1 month to &lt;4 years, who were administered Lacosamide oral solution (for subjects weighing &lt;50 kg) or tablet (for subjects weighing &gt;=50 kg). The initial dose of 2 mg/kg/day (for subjects weighing &lt;50 kg), or 100 mg/day (for subjects weighing &gt;=50 kg) was titrated to optimize tolerability and seizure control to at least 4 mg/kg/day for subjects weighing &lt;50 kg, or 200 mg/day for subjects weighing &gt;=50 kg; not to exceed 12 mg/kg/day for subjects weighing &lt;50 kg, or 600 mg/day in subjects weighing &gt;=50 kg.</description>
          </group>
          <group group_id="O2">
            <title>Lacosamide 4 Years - &lt;2 Years SS</title>
            <description>Subjects, aged 4 years to &lt;12 years, who were administered Lacosamide oral solution (for subjects weighing &lt;50 kg) or tablet (for subjects weighing &gt;=50 kg). The initial dose of 2 mg/kg/day (for subjects weighing &lt;50 kg), or 100 mg/day (for subjects weighing &gt;=50 kg) was titrated to optimize tolerability and seizure control to at least 4 mg/kg/day for subjects weighing &lt;50kg, or 200 mg/day for subjects weighing &gt;=50 kg; not to exceed 12 mg/kg/day for subjects weighing &lt;50 kg, or 600 mg/day in subjects weighing &gt;=50 kg.</description>
          </group>
          <group group_id="O3">
            <title>Lacosamide 12 Years - &lt;18 Years SS</title>
            <description>Subjects, aged 12 years to &lt;18 years, who were administered Lacosamide oral solution (for subjects weighing &lt;50 kg) or tablet (for subjects weighing &gt;=50 kg). The initial dose of 2 mg/kg/day (for subjects weighing &lt;50 kg), or 100 mg/day (for subjects weighing &gt;=50 kg) was titrated to optimize tolerability and seizure control to at least 4 mg/kg/day for subjects weighing &lt;50kg, or 200 mg/day for subjects weighing &gt;=50 kg; not to exceed 12 mg/kg/day for subjects weighing &lt;50 kg, or 600 mg/day in subjects weighing &gt;=50 kg.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subject Withdrawals Due to Adverse Events From Baseline to End of Study (Approximately 32 Weeks)</title>
          <description>An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment.</description>
          <population>The Safety Set (SS) included all enrolled subjects who took at least 1 dose of lacosamide (LCM).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Experiencing at Least 1 Treatment-emergent Adverse Event From Baseline to End of Study (Approximately 32 Weeks)</title>
        <description>An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment.</description>
        <time_frame>From Baseline to End of Study (approximately 32 weeks)</time_frame>
        <population>The Safety Set (SS) included all enrolled subjects who took at least 1 dose of lacosamide (LCM).</population>
        <group_list>
          <group group_id="O1">
            <title>Lacosamide 1 Month - &lt;4 Years SS</title>
            <description>Subjects, aged 1 month to &lt;4 years, who were administered Lacosamide oral solution (for subjects weighing &lt;50 kg) or tablet (for subjects weighing &gt;=50 kg). The initial dose of 2 mg/kg/day (for subjects weighing &lt;50 kg), or 100 mg/day (for subjects weighing &gt;=50 kg) was titrated to optimize tolerability and seizure control to at least 4 mg/kg/day for subjects weighing &lt;50 kg, or 200 mg/day for subjects weighing &gt;=50 kg; not to exceed 12 mg/kg/day for subjects weighing &lt;50 kg, or 600 mg/day in subjects weighing &gt;=50 kg.</description>
          </group>
          <group group_id="O2">
            <title>Lacosamide 4 Years - &lt;2 Years SS</title>
            <description>Subjects, aged 4 years to &lt;12 years, who were administered Lacosamide oral solution (for subjects weighing &lt;50 kg) or tablet (for subjects weighing &gt;=50 kg). The initial dose of 2 mg/kg/day (for subjects weighing &lt;50 kg), or 100 mg/day (for subjects weighing &gt;=50 kg) was titrated to optimize tolerability and seizure control to at least 4 mg/kg/day for subjects weighing &lt;50kg, or 200 mg/day for subjects weighing &gt;=50 kg; not to exceed 12 mg/kg/day for subjects weighing &lt;50 kg, or 600 mg/day in subjects weighing &gt;=50 kg.</description>
          </group>
          <group group_id="O3">
            <title>Lacosamide 12 Years - &lt;18 Years SS</title>
            <description>Subjects, aged 12 years to &lt;18 years, who were administered Lacosamide oral solution (for subjects weighing &lt;50 kg) or tablet (for subjects weighing &gt;=50 kg). The initial dose of 2 mg/kg/day (for subjects weighing &lt;50 kg), or 100 mg/day (for subjects weighing &gt;=50 kg) was titrated to optimize tolerability and seizure control to at least 4 mg/kg/day for subjects weighing &lt;50kg, or 200 mg/day for subjects weighing &gt;=50 kg; not to exceed 12 mg/kg/day for subjects weighing &lt;50 kg, or 600 mg/day in subjects weighing &gt;=50 kg.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Experiencing at Least 1 Treatment-emergent Adverse Event From Baseline to End of Study (Approximately 32 Weeks)</title>
          <description>An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment.</description>
          <population>The Safety Set (SS) included all enrolled subjects who took at least 1 dose of lacosamide (LCM).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected throughout the study (up to week 26)</time_frame>
      <desc>An Adverse Event (AE) was any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that did not necessarily have a causal relationship with this treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Lacosamide 1 Month - &lt;4 Years</title>
          <description>Subjects, aged 1 month to &lt;4 years, who were administered Lacosamide oral solution (for subjects weighing &lt;50 kg) or tablet (for subjects weighing &gt;=50 kg). The initial dose of 2 mg/kg/day (for subjects weighing &lt;50 kg), or 100 mg/day (for subjects weighing &gt;=50 kg) was titrated to optimize tolerability and seizure control to at least 4 mg/kg/day for subjects weighing &lt;50 kg, or 200 mg/day for subjects weighing &gt;=50 kg; not to exceed 12 mg/kg/day for subjects weighing &lt;50 kg, or 600 mg/day in subjects weighing &gt;=50 kg.</description>
        </group>
        <group group_id="E2">
          <title>Lacosamide 4 Years - &lt;12 Years</title>
          <description>Subjects, aged 4 years to &lt;12 years, who were administered Lacosamide oral solution (for subjects weighing &lt;50 kg) or tablet (for subjects weighing &gt;=50 kg). The initial dose of 2 mg/kg/day (for subjects weighing &lt;50 kg), or 100 mg/day (for subjects weighing &gt;=50 kg) was titrated to optimize tolerability and seizure control to at least 4 mg/kg/day for subjects weighing &lt;50kg, or 200 mg/day for subjects weighing &gt;=50 kg; not to exceed 12 mg/kg/day for subjects weighing &lt;50 kg, or 600 mg/day in subjects weighing &gt;=50 kg.</description>
        </group>
        <group group_id="E3">
          <title>Lacosamide 12 Years - &lt;18 Years</title>
          <description>Subjects, aged 12 years to &lt;18 years, who were administered Lacosamide oral solution (for subjects weighing &lt;50 kg) or tablet (for subjects weighing &gt;=50 kg). The initial dose of 2 mg/kg/day (for subjects weighing &lt;50 kg), or 100 mg/day (for subjects weighing &gt;=50 kg) was titrated to optimize tolerability and seizure control to at least 4 mg/kg/day for subjects weighing &lt;50kg, or 200 mg/day for subjects weighing &gt;=50 kg; not to exceed 12 mg/kg/day for subjects weighing &lt;50 kg, or 600 mg/day in subjects weighing &gt;=50 kg.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA16.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA16.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="24"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="7" subjects_affected="4" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>UCB</name_or_title>
      <organization>Cares</organization>
      <phone>+1844 599 ext 2273</phone>
      <email>UCBCares@ucb.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

